Idera Pharmaceuticals Announces Presentation Of Preclinical Data Of IMO-8400 In Both Lupus And Psoriasis Models
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will
be presenting data from preclinical studies of its Toll-like receptor
(TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications. The data from the SLE model will be presented in an oral presentation at the American Association of Immunologists (AAI) meeting in Boston, Massachusetts at 8:00a.m. ET on May 5, 2012. The oral presentation, entitled “IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice,” will be made during the session “Therapeutic Strategies for Rheumatologic Diseases.” Idera expects to submit to the FDA an Investigational New Drug application for IMO-8400 during the fourth quarter of 2012, and has selected lupus as the initial disease indication for clinical development. In addition to the oral presentation, a poster presentation entitled “IMO-8400, a novel TLR7, TLR8, and TLR9 antagonist, inhibits disease development in mouse models of psoriasis” is scheduled for May 6, 2012, in the session “Novel and Cellular Approaches to Autoimmunity” during AAI. About TLRs and Idera’s Pipeline Toll-like Receptors (TLRs) represent a class of proteins that play a key role in both inflammation and immunity. Of the 10 human TLRs identified to date, Idera is focusing on compounds targeted to TLRs 3, 7, 8, and 9, which are expressed in different cells and serve unique functions. For example, activation of TLR7 and TLR9 present in certain dendritic cells and lymphocytes may be useful for the treatment of various types of cancer by stimulating immunity. In contrast, inhibition of specific TLRs may be useful in treating autoimmune disorders, such as psoriasis and lupus, by blocking the production of multiple pro-inflammatory mediators. Using its chemistry-based approach, Idera is advancing novel drug candidates to modulate immune response through activation or inhibition of specific TLRs to treat a broad range of diseases, including autoimmune diseases and cancer, and to enhance the effectiveness of vaccines.